TY  - JOUR
AU  - Asselah, Tarik
AU  - Thompson, Alex J
AU  - Flisiak, Robert
AU  - Romero-Gomez, Manuel
AU  - Messinger, Diethelm
AU  - Bakalos, Georgios
AU  - Shiffman, Mitchell L
PY  - 2016
DO  - 10.1371/journal.pone.0150569
UR  - http://hdl.handle.net/10668/9928
T2  - PloS one
AB  - Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - Hepatitis C, Chronic
KW  - Humans
KW  - Interferon-alpha
KW  - Male
KW  - Middle Aged
KW  - Models, Theoretical
KW  - Polyethylene Glycols
KW  - Recombinant Proteins
KW  - Retrospective Studies
KW  - Ribavirin
KW  - Viral Load
KW  - Young Adult
TI  - A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
TY  - research article
VL  - 11
ER  -